m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00771)
Target Name Lactate dehydrogenase A (LDHA)
Synonyms
L-lactate dehydrogenase A chain; LDH-A; EC 1.1.1.27 ; Cell proliferation-inducing gene 19 protein ; LDH muscle subunit; LDH-M ; Renal carcinoma antigen NY-REN-59
    Click to Show/Hide
Gene Name LDHA
Chromosomal Location 11p15.1
Family LDH/MDH superfamily, LDH family
Function
Interconverts simultaneously and stereospecifically pyruvate and lactate with concomitant interconversion of NADH and NAD(+).
    Click to Show/Hide
Gene ID 3939
Uniprot ID
LDHA_HUMAN
HGNC ID
HGNC:6535
Ensembl Gene ID
ENSG00000134333.14
KEGG ID
hsa:3939
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
LDHA can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 enhances the expression of Lactate dehydrogenase A (LDHA), which catalyzes the conversion of pyruvate to lactate, to trigger glycolysis and 5-FU resistance. METTL3/LDHA axis-induced glucose metabolism is a potential therapy target to overcome 5-FU resistance in CRC cells.
Target Regulation Up regulation
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Pathway Response HIF-1 signaling pathway hsa04066
Glycolysis / Gluconeogenesis hsa00010
Cell Process Glycolysis
In-vitro Model HCT 116 Colon carcinoma Homo sapiens CVCL_0291
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
In-vivo Model For subcutaneous transplanted model, sh-control and sh-METTL3 HCT-116/5-FU cells (5 × 106 per mouse) were diluted in 100ul PBS + 100 ul Matrigel (BD Biosciences, San Jose, CA, USA) and injected subcutaneously in the rear flank fat pad of the nude mice.
Colorectal cancer [ICD-11: 2B91]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 enhances the expression of Lactate dehydrogenase A (LDHA), which catalyzes the conversion of pyruvate to lactate, to trigger glycolysis and 5-FU resistance. METTL3/LDHA axis-induced glucose metabolism is a potential therapy target to overcome 5-FU resistance in CRC cells.
Responsed Disease Colorectal cancer [ICD-11: 2B91]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response HIF-1 signaling pathway hsa04066
Glycolysis / Gluconeogenesis hsa00010
Cell Process Glycolysis
In-vitro Model HCT 116 Colon carcinoma Homo sapiens CVCL_0291
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
In-vivo Model For subcutaneous transplanted model, sh-control and sh-METTL3 HCT-116/5-FU cells (5 × 106 per mouse) were diluted in 100ul PBS + 100 ul Matrigel (BD Biosciences, San Jose, CA, USA) and injected subcutaneously in the rear flank fat pad of the nude mice.
References
Ref 1 N(6)-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming. Theranostics. 2022 Jun 13;12(10):4802-4817. doi: 10.7150/thno.73746. eCollection 2022.